IL-23-Induced Psoriasis Model Development Services

The interleukin-23 (IL-23)-induced psoriasis model has emerged as a pivotal tool in dermatological research, offering a comprehensive platform to study the intricate interplay of genetic, immunological, and environmental factors implicated in the disease. At Ace Therapeutics, we specialize in providing comprehensive services for the development and validation of IL-23-induced psoriasis mouse models.

Introduction to IL-23-Induced Psoriasis Model

Psoriasis is a chronic, immune-mediated skin disorder characterized by erythematous plaques with silvery scales, resulting from aberrant interactions between keratinocytes and immune cells. Among the cytokines implicated in its pathogenesis, IL-23 plays a pivotal role. IL-23 is critical for the differentiation and maintenance of Th17 cells, which secrete IL-17 and IL-22, cytokines that are essential for the inflammatory cascade observed in psoriasis. To facilitate the understanding and treatment of psoriasis, IL-23-induced psoriasis models have been developed. These models closely mimic the pathological features of human psoriasis, providing a robust platform for preclinical research.

Fig. 1 Schematic representation of IL-23-producing cells and IL-23 target cells implicated in PsO, PsA, and IBD pathogenesis. (Krueger JG, et al., 2024)

Our IL-23-Induced Psoriasis Model Development Services

At Ace Therapeutics, we have developed and meticulously characterized a range of mouse models that faithfully recapitulate the IL-23-driven pathogenesis of psoriasis. These models serve as invaluable tools for our clients to evaluate the efficacy and safety of novel therapeutic candidates targeting the IL-23/IL-17 axis.

• Model Development
  At Ace Therapeutics, our team has extensive expertise in establishing and characterizing IL-23-induced psoriasis models. Following well-established protocols, we carefully administer recombinant IL-23 via intradermal or systemic routes in mice. Our IL-23 induced psoriasis mouse models reliably recapitulate key psoriasis features including marked epidermal hyperplasia, pronounced hyperkeratosis, and robust immune cell recruitment (particularly Th17 cells).
• Pathophysiological Services
  We specialize in collaborating with our clients to conduct comprehensive studies aimed at elucidating the pathophysiological mechanisms underlying psoriasis in our IL-23-induced mouse models. By examining the interplay between IL-23, IL-17, IL-22, and other cytokines, we provide insights into the inflammatory pathways that drive the disease.
• Genetic Modification Services
  Our expertise extends to genetic modification studies, where we employ IL-23-induced psoriasis models to investigate the effects of specific gene alterations. By using genetic engineering techniques such as CRISPR/Cas9, we can knock out or overexpress target genes to study their role in psoriasis.
• Preclinical Evaluation Services
  Leveraging these well-established IL-23-induced mouse models, Ace Therapeutics offers a comprehensive suite of preclinical evaluation services to our clients. We work closely with pharmaceutical companies and academic researchers to design and execute tailored studies to assess the efficacy and safety of novel therapeutic candidates targeting the IL-23/IL-17 axis.

Our Advantages in IL-23-Induced Psoriasis Model Development

To learn more about how Ace Therapeutics can support your psoriasis research efforts using our IL-23-induced mouse model, please do not hesitate to contact us. Our expert team is dedicated to collaborating with you and delivering high-quality data to accelerate your drug discovery and development programs.